NASDAQ · ELAB

PMGC Holdings Inc.

$0.92 +$0.02 (+2.21%) 1D After hours

Key Metrics

$4.09M
Market cap
P/E · TTM
$1.27M
Revenue · TTM
−$11.11M
Net income
EPS · TTM $-1,712.66
Dividend yield
Free cash flow −$8.36M
Beta · 1Y 2.88
EBITDA · TTM −$7.48M
Gross margin 32.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 30 high, the share price fell 96%.

    Peak close $21.06 on Jan 30; trough close $0.90 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -96%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 1
    The stock moved +133.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 1
  • Mar 30
    The stock moved +113.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.09M
Enterprise value
Shares outstanding4.5M
52-wk range$0.84 – $57.54
Avg volume · 20D1.2M
Net cash
Book value / share$1,943.94
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About PMGC Holdings Inc.
IPO dateNov 21, 2023
Employees34

PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S3.21
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 32.7%
Operating -609.2%
Net -873.1%
FCF -657.4%
ROE / ROIC -115.3% · —

Financial Health

Current ratio1.45
Quick ratio1.43
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.09M

Cash Flow · TTM

Operating CF −$7.57M
Capex −$796.18K
Free cash flow −$8.36M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-1.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings